When is Genmab AS's (GMAB) next earnings report?

Genmab AS's next earnings report is expected on August 6, 2026 (71 days away). View GMAB's historical earnings reactions and AI-powered earnings trade plan on Trend Edge at https://trendedge.app/asset/GMAB

What is Genmab AS's (GMAB) market cap?

Genmab AS has a market cap of $16.71B, classifying it as a large-cap Healthcare stock. Trend Edge tracks GMAB's institutional ownership (13.6%), insider transactions, and proprietary indicators.

Is Genmab AS (GMAB) founder-led?

Yes — Genmab AS is founder-led. Current founder leadership: Jan Van de Winkel (President & Chief Executive Officer). Founder-led companies are tracked separately by Trend Edge as a proprietary indicator.

What is GMAB's Trend Edge Score?

GMAB's current Trend Edge Score is 23.5. The Trend Edge Score is a proprietary technical indicator combining weekly trend strength, momentum, and volume signals into a single value used to rank long position setups across thousands of tracked stocks.

How has GMAB historically reacted to earnings?

Over the last 68 earnings events, GMAB has averaged a 0.45% return in the week following earnings, with a 50.00% win rate. Best 1-week reaction: +14.13%. Worst: -37.64%. Full earnings reaction breakdown across gap, 1-day, 2-week, and 1-month timeframes available on Trend Edge.

What is the average analyst price target for GMAB?

9 Wall Street analysts have an average price target of $37.55 on GMAB, implying 39.7% upside from the current price of $26.87.

GMAB Stock Analysis — Genmab AS · Founder-Led

About Genmab AS

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after che… Read full Trend Edge analysis →

Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
IPO Date: June 1, 2009
Headquarters: Carl Jacobsens Vej 30, Copenhagen, Denmark, 2500
Website: https://www.genmab.com
Employees: 3,088

Key Metrics

Current Price	$26.87
Market Cap	$16.71B
Float	60.6M
Shares Outstanding	613.9M
P/E (Forward)	16.03
P/E (TTM)	20.77
Price/Sales (TTM)	4.28
vs. Analyst Target	+39.7% to analyst PT
Profit Margin	21.05%
Operating Margin (TTM)	25.11%
Revenue (TTM)	$3.90B
Earnings Growth (YoY)	-72.80%
Dividend Rate	None
Analyst Target Price	$37.55 (9 analysts)

Financial History

Annual Revenue & Earnings History

Year	Revenue	Net Income	Gross Profit	EBITDA
2020	$10.11B	$4.76B	$10.11B	$6.16B
2021	$8.42B	$2.96B	$8.42B	$4.18B
2022	$14.51B	$5.45B	$14.51B	$7.35B
2023	$16.47B	$4.35B	$16.25B	$5.95B
2024	$21.53B	$7.84B	$20.54B	$9.70B
2025	$3.72B	$964M	$3.41B	$1.32B

Recent Quarterly Revenue & Net Income

Quarter	Revenue	Net Income
Jun 2025	$5.86B	$2.13B
Sep 2025	$1.02B	$401M
Dec 2025	$1.05B	$30.9M
Mar 2026	$899M	$53.2M

Institutional Ownership	13.6%
Short Float	14.0%
% of All Funds Holding	3.09%
Number of Funds Holding	254

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

Timeframe	SMA	Value	Trend Context
Weekly	10-Week SMA	$26.84	Near-term / short-term trend
Weekly	40-Week SMA	$29.40	Medium-term trend
Weekly	80-Week SMA	$25.22	Cyclical trend (business cycle)
Weekly	200-Week SMA	$30.35	Secular trend (multi-year)
Monthly	10-Month SMA	$28.96	Near-term monthly trend
Monthly	20-Month SMA	$25.03	Medium-term monthly trend
Monthly	40-Month SMA	$28.69	Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price Level	Type	Volume Ratio	Age
$29.40	resistance	1.01x	1 months ago
$25.80	support	1.30x	7 months ago
$19.10	support	1.35x	12 months ago
$19.10	support	1.32x	14 months ago

Historical Earnings Reactions (68 events)

Timeframe	Avg Return	Median	Win Rate	Best	Worst
Gap	0.22%	0.04%	50.00%	8.99%	-31.73%
1 Day	0.37%	0.00%	48.53%	12.21%	-31.73%
1 Week	0.45%	0.22%	50.00%	14.13%	-37.64%
2 Weeks	-0.65%	0.00%	48.53%	22.38%	-49.83%
1 Month	0.33%	1.63%	52.24%	55.96%	-48.46%

Next earnings: August 6, 2026 (71 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

Month	Avg Return	Win Rate	Samples
Jan	0.5%	35.3%	17
Feb	4.2%	47.1%	17
Mar	-0.4%	47.1%	17
Apr	2.2%	47.1%	17
May	2.6%	56.3%	16
Jun	1.3%	56.3%	16
Jul	7.2%	76.5%	17
Aug	-2.1%	52.9%	17
Sep	1.0%	35.3%	17
Oct	0.6%	47.1%	17
Nov	3.0%	52.9%	17
Dec	1.6%	47.1%	17

Day-of-Week Tendencies

Day	Avg Return	Win Rate	Samples
Monday	0.12%	39.3%	800
Tuesday	-0.01%	34.4%	878
Wednesday	0.11%	36.6%	875
Thursday	0.05%	38.9%	859
Friday	0.19%	38.9%	855

Insider Transactions — Smart Summary

Founder-led management: Jan Van de Winkel (President & Chief Executive Officer)

12-Month Insider Activity Summary

Total Filings	4
Net Value	+N/A
Net Shares Change	-73,445,983
% of Float	-121.1%
C-Suite Filings	0
Clusters Detected	0

Key Insiders

Name	Title	Net Value	Filings	Activity
GENMAB A/S		-$7.12B	4	4 buy

Significant Filings

Date	Insider	Net Value	Price After
2025-12-30	GENMAB A/S	-$7.26B	Transaction at $97.00, now -72.3%
2025-12-29	GENMAB A/S	+$79.1M	Transaction at $97.00, now -72.3%
2025-12-22	GENMAB A/S	+$27.0M	Transaction at $97.00, now -72.3%
2025-12-18	GENMAB A/S	+$26.3M	Transaction at $97.00, now -72.3%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Genmab AS (GMAB) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for GMAB on Trend Edge →

GMAB — Genmab AS

About Genmab AS

Trend Edge Proprietary Indicators

Key Metrics

Financial History

Annual Revenue & Earnings History

Recent Quarterly Revenue & Net Income

Ownership & Float

Current Moving Averages

Volume Shelves — Support & Resistance

Historical Earnings Reactions (68 events)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

Day-of-Week Tendencies

Top Institutional Holders

Insider Transactions — Smart Summary

12-Month Insider Activity Summary

Key Insiders

Significant Filings

AI Consult Analysis

GMAB — Genmab AS

About Genmab AS

Trend Edge Proprietary Indicators

Key Metrics

Financial History

Annual Revenue & Earnings History

Recent Quarterly Revenue & Net Income

Ownership & Float

Current Moving Averages

Volume Shelves — Support & Resistance

Historical Earnings Reactions (68 events)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

Day-of-Week Tendencies

Top Institutional Holders

Insider Transactions — Smart Summary

12-Month Insider Activity Summary

Key Insiders

Significant Filings

AI Consult Analysis

Related Biotechnology Stocks